IBRX IMMUNITYBIO INC revenue, earnings and financials
For the quarter ended June 30, 2026, IMMUNITYBIO INC reported revenue of $51.2M (up 93.9% from a year earlier), net income of −$230M and diluted EPS of −$0.22; over the last four quarters revenue was $166M and net income −$992M; for the fiscal year ended December 2025 revenue was $113M, up 668.3% on the year before.
IBRX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $113M, gross profit n/a, operating income −$256M, net income −$352M (margin -310.3%), EPS −$0.38
- Fiscal year ended Dec 2024: revenue $14.7M, gross profit n/a, operating income −$344M, net income −$414M (margin -2805.0%), EPS −$0.62
- Fiscal year ended Dec 2023: revenue $622K, gross profit n/a, operating income −$362M, net income −$584M (margin -93874.6%), EPS −$1.15
- Fiscal year ended Dec 2022: revenue $240K, gross profit n/a, operating income −$351M, net income −$417M (margin -173875.0%), EPS −$1.04
- Fiscal year ended Dec 2021: revenue $934K, gross profit n/a, operating income −$330M, net income −$350M (margin -37451.8%), EPS −$0.89
IBRX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $51.2M (up 93.9% year over year), net income −$230M, EPS −$0.22
- Quarter ended Mar 31, 2026: revenue $44.2M (up 167.6% year over year), net income −$633M, EPS −$0.62
- Quarter ended Dec 31, 2025 (from the annual report): revenue $38.3M (up 407.0% year over year), net income −$62.0M, EPS −$0.06
- Quarter ended Sep 30, 2025: revenue $32.1M (up 425.1% year over year), net income −$67.3M, EPS −$0.07
- Quarter ended Jun 30, 2025: revenue $26.4M (up 2423.9% year over year), net income −$92.6M, EPS −$0.10
- Quarter ended Mar 31, 2025: revenue $16.5M (up 41192.5% year over year), net income −$130M, EPS −$0.15
- Quarter ended Dec 31, 2024 (from the annual report): revenue $7.55M (up 5333.1% year over year), net income −$59.2M, EPS −$0.08
- Quarter ended Sep 30, 2024: revenue $6.11M (up 7346.3% year over year), net income −$85.7M, EPS −$0.14
- Quarter ended Jun 30, 2024: revenue $1.05M (up 2453.7% year over year), net income −$135M, EPS −$0.20
- Quarter ended Mar 31, 2024: revenue $40.0K (down 88.9% year over year), net income −$134M, EPS −$0.20
- Quarter ended Dec 31, 2023 (from the annual report): revenue $139K (up 90.4% year over year), net income −$234M, EPS −$0.37
- Quarter ended Sep 30, 2023: revenue $82.0K (down 30.5% year over year), net income −$95.6M, EPS −$0.19
- Quarter ended Jun 30, 2023: revenue $41.0K (up 17.1% year over year), net income −$138M, EPS −$0.32
- Quarter ended Mar 31, 2023: revenue $360K (up 2471.4% year over year), net income −$116M, EPS −$0.27
- Quarter ended Dec 31, 2022 (from the annual report): revenue $73.0K (down 81.3% year over year), net income −$109M, EPS −$0.26
- Quarter ended Sep 30, 2022: revenue $118K (up 78.8% year over year), net income −$111M, EPS −$0.28
- Quarter ended Jun 30, 2022: revenue $35.0K (down 89.7% year over year), net income −$94.6M, EPS −$0.24
- Quarter ended Mar 31, 2022: revenue $14.0K (down 89.9% year over year), net income −$103M, EPS −$0.26
- Quarter ended Dec 31, 2021 (from the annual report): revenue $390K, net income −$94.3M, EPS −$0.23
- Quarter ended Sep 30, 2021: revenue $66.0K, net income −$87.6M, EPS −$0.22
IBRX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$305M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$391M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$367M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$338M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$274M, share buybacks $0
IBRX balance sheet
- Jun 30, 2026: cash $75.7M, total assets $629M, total liabilities $1.67B, shareholders' equity −$1.05B
- Mar 31, 2026: cash $205M, total assets $647M, total liabilities $1.52B, shareholders' equity −$870M
- Dec 31, 2025: cash $88.3M, total assets $502M, total liabilities $1.00B, shareholders' equity −$500M
- Sep 30, 2025: cash $60.2M, total assets $519M, total liabilities $1.04B, shareholders' equity −$524M
- Jun 30, 2025: cash $138M, total assets $402M, total liabilities $972M, shareholders' equity −$571M
- Mar 31, 2025: cash $60.7M, total assets $304M, total liabilities $894M, shareholders' equity −$591M
- Dec 31, 2024: cash $143M, total assets $383M, total liabilities $871M, shareholders' equity −$489M
- Sep 30, 2024: cash $112M, total assets $365M, total liabilities $1.11B, shareholders' equity −$745M
What is IBRX's revenue?
IMMUNITYBIO INC reported $166M of revenue over its last four quarters, through June 30, 2026.
Is IBRX profitable?
No. IMMUNITYBIO INC lost $992M over the last four quarters.
What is IBRX's EPS?
Diluted earnings per share over the last four quarters were −$0.97; −$0.22 in the latest quarter.